Trial Profile
A Study to Evaluate the Potential of Concomitant Ramucirumab to Affect the Pharmacokinetics of Paclitaxel in Patients With Advanced Malignant Solid Tumors.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Mar 2022
Price :
$35
*
At a glance
- Drugs Ramucirumab (Primary) ; Paclitaxel
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 10 Mar 2021 Status changed from active, no longer recruiting to completed.
- 02 Jan 2020 Planned End Date changed from 1 Jan 2020 to 1 Jan 2021.
- 17 Jul 2019 Planned End Date changed from 31 Dec 2018 to 1 Jan 2020.